Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment

Although lower-grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1 mutant patients are increasingly being treated with temozolomide (TMZ), but early detection of response remains...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Res
Asıl Yazarlar: Subramani, Elavarasan, Radoul, Marina, Najac, Chloe, Batsios, Georgios, Molloy, Abigail R., Hong, Donghyun, Gillespie, Anne Marie, Santos, Romelyn Delos, Viswanath, Pavithra, Costello, Joseph F., Pieper, Russell O., Ronen, Sabrina M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669718/
https://ncbi.nlm.nih.gov/pubmed/32958546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-1314
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller